Synthetic aminoglycoside derivatives as anti-virulence agents against multidrug-resistant Acinetobacter baumannii
A systematic review
Keywords:
AbaR, Acinetobacter baumannii, aminoglycoside derivatives, BfmR, biofilm inhibition, molecular docking, quorum sensingAbstract
Acinetobacter baumannii presents a severe clinical challenge in critical care due to its rapid acquisition of drug resistance and its ability to form dense biofilms on medical equipment. While traditional antibiotic research focuses almost exclusively on essential bacterial viability targets, targeting virulence factors at sub-inhibitory concentrations (sub-MIC) offers an alternative approach to reduce pathogen persistence without driving immediate resistance. This systematic review synthesizes the literature published between January 2010 and July 2026 that evaluates chemically modified aminoglycoside derivatives designed to bypass aminoglycoside-modifying enzymes (AMEs) and impair A. baumannii virulence pathways. Evidence from the included studies indicates that targeted modifications to the 2-deoxystreptamine core, specifically inserting hydrophobic or amphiphilic side chains, restore susceptibility in carbapenem-resistant A. baumannii (CRAB) strains. Furthermore, these derivatives significantly reduce biofilm biomass (often by over 80% at 21×MIC) and restrict surface twitching motility. Computational docking models across these studies point to multi-target engagement, where modified derivatives interact directly with outer membrane protein A (OmpA), the quorum-sensing receptor AbaR, and the response regulator BfmR. Rational scaffold engineering of aminoglycosides offers a viable approach to develop dual-action agents that combine direct antibacterial activity with phenotypic disarming.
Downloads
References
Ayoub Moubareck, C., & Hammoudi Halat, D. (2020). Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics, 9(3), 119. DOI: https://doi.org/10.3390/antibiotics9030119
Cisneros, J. M., & Rodríguez-Baño, J. (2002). Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clinical Microbiology and Infection, 8(11), 687-693. DOI: https://doi.org/10.1046/j.1469-0691.2002.00487.x
Eijkelkamp, B. A., Stroeher, U. H., Hassan, K. A., Paulsen, I. T., & Brown, M. H. (2014). Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii. BMC genomics, 15(1), 1020. DOI: https://doi.org/10.1186/1471-2164-15-1020
Elanany, A. A., Khalifa, A. G., & Attia, A. S. (2025). Antivirulence drugs against Acinetobacter baumannii: where do they stand?. World Journal of Microbiology and Biotechnology, 41(11), 424. DOI: https://doi.org/10.1007/s11274-025-04593-3
Ganić, T., Vuletić, S., Nikolić, B., Stevanović, M., Kuzmanović, M., Kekić, D., ... & Mitić-Ćulafić, D. (2022). Cinnamon essential oil and its emulsion as efficient antibiofilm agents to combat Acinetobacter baumannii. Frontiers in Microbiology, 13, 989667. DOI: https://doi.org/10.3389/fmicb.2022.989667
Gao, W., et al. (2020). Structural basis of quorum sensing inhibition in Acinetobacter baumannii. ACS Infectious Diseases, 6(8), 2105–2114.
Gopikrishnan, M., & Kumar, D. T. (2026). Computational exploration of high-throughput virtual screening and molecular dynamics analysis targeting BfmR in Acinetobacter baumannii: Towards anti-virulent therapeutics. Advances in Protein Chemistry and Structural Biology, 153, 455-484. https://doi.org/10.1016/bs.apcsb.2026.06.013 DOI: https://doi.org/10.1016/bs.apcsb.2026.06.013
Imperi, F., Fiscarelli, E. V., Visaggio, D., Leoni, L., & Visca, P. (2019). Activity and impact on resistance development of two antivirulence fluoropyrimidine drugs in Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 9, 49. DOI: https://doi.org/10.3389/fcimb.2019.00049
Kim, H. J., Kim, N. Y., Ko, S. Y., Park, S. Y., Oh, M. H., Shin, M. S., ... & Lee, J. C. (2022). Complementary regulation of BfmRS two-component and AbaIR quorum sensing systems to express virulence-associated genes in Acinetobacter baumannii. International Journal of Molecular Sciences, 23(21), 13136. DOI: https://doi.org/10.3390/ijms232113136
Lim, S. M. S., Abidin, A. Z., Liew, S. M., Roberts, J. A., & Sime, F. B. (2019). The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. Journal of infection, 79(6), 593-600. https://doi.org/10.1016/j.jinf.2019.09.012 DOI: https://doi.org/10.1016/j.jinf.2019.09.012
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008). Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews, 21(3), 538-582. DOI: https://doi.org/10.1128/CMR.00058-07
Ramirez, M. S., & Tolmasky, M. E. (2010). Aminoglycoside modifying enzymes. Drug resistance updates, 13(6), 151-171. https://doi.org/10.1016/j.drup.2010.08.003 DOI: https://doi.org/10.1016/j.drup.2010.08.003
Sati, H., Carrara, E., Savoldi, A., Hansen, P., Garlasco, J., Campagnaro, E., ... & Nyaruhirira, A. U. (2025). The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet infectious diseases, 25(9), 1033-1043. DOI: https://doi.org/10.1016/S1473-3099(25)00118-5
Tang, K., Zhang, X., & Ni, B. (2021). Quorum sensing inhibition or quenching in Acinetobacter baumannii: The novel therapeutic strategies for new drug development. Frontiers in Microbiology, 12, 558003. DOI: https://doi.org/10.3389/fmicb.2021.558003
Tapia-Rodriguez, M. R., Cantu-Soto, E. U., Vazquez-Armenta, F. J., Bernal-Mercado, A. T., & Ayala-Zavala, J. F. (2023). Inhibition of Acinetobacter baumannii biofilm formation by terpenes from Oregano (Lippia graveolens) essential oil. Antibiotics, 12(10), 1539.
Tapia-Rodriguez, M. R., Cantu-Soto, E. U., Vazquez-Armenta, F. J., Bernal-Mercado, A. T., & Ayala-Zavala, J. F. (2023). Inhibition of Acinetobacter baumannii biofilm formation by terpenes from Oregano (Lippia graveolens) essential oil. Antibiotics, 12(10), 1539. DOI: https://doi.org/10.3390/antibiotics12101539
Tomaras, A. P., Dorsey, C. W., Edelmann, R. E., & Actis, L. A. (2003). Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology, 149(12), 3473-3484. DOI: https://doi.org/10.1099/mic.0.26541-0
Published
How to Cite
Issue
Section
Copyright (c) 2026 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
